In a preclinical trial using a Rit1 mouse model of NS (Castel et al., 2019), treatment with trametinib prevented progression of cardiac hypertrophy, as determined by heart weight and myocyte size. This evidence concerns the gene RIT1 and cardiac hypertrophy.